Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.. Daily Stock Analysis

Daily Stock Analysis, BPMP, Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts., priceseries

Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.. Daily Stock Analysis
Stock Information
Open
16.05
Close
16.33
High
16.47
Low
16.02
Previous Close
16.05
Daily Price Gain
0.28
YTD High
19.37
YTD High Date
Feb 11, 2022
YTD Low
15.20
YTD Low Date
Jan 3, 2022
YTD Price Change
0.57
YTD Gain
3.62%
52 Week High
19.37
52 Week High Date
Feb 11, 2022
52 Week Low
11.22
52 Week Low Date
Mar 8, 2021
52 Week Price Change
4.88
52 Week Gain
42.61%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 26. 2018
12.98
May 24. 2018
14.80
20 Trading Days
14.01%
Link
LONG
Dec 31. 2018
11.47
Jan 14. 2019
12.17
9 Trading Days
6.17%
Link
LONG
Dec 18. 2019
12.19
Jan 21. 2020
13.17
21 Trading Days
7.98%
Link
LONG
Apr 6. 2020
7.38
May 1. 2020
9.40
18 Trading Days
27.45%
Link
LONG
May 15. 2020
9.73
Jun 9. 2020
10.57
16 Trading Days
8.61%
Link
LONG
Nov 13. 2020
9.64
Dec 7. 2020
10.21
15 Trading Days
5.92%
Link
LONG
Jan 5. 2021
9.83
Jan 20. 2021
11.24
10 Trading Days
14.34%
Link
LONG
Apr 22. 2021
12.02
May 19. 2021
12.94
19 Trading Days
7.70%
Link
LONG
Jan 3. 2022
15.76
Jan 21. 2022
17.62
13 Trading Days
11.79%
Link
Company Information
Stock Symbol
BPMP
Exchange
NASDAQ
Company URL
http://www.blueprintmedicines.com
Company Phone
617-374-7580
CEO
Jeffrey W. Albers
Headquarters
Massachusetts
Business Address
38 SIDNEY STREET, SUITE 200, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001597264
About

Blueprint Medicines Corp. is a biopharmaceutical company, which engages in developing of kinase inhibitors for genomically defined subsets of cancer patients. It has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling the development of potent highly selective compounds against clear genomic driver targets. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.

Description

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing treatments that target cancer and rare genetic diseases. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading